lead in Biological Technology

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

... by a significant achievement for Amicus with our lead program, Amigal for Fabry disease, entering Phase ... of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal ... to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal ...

Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSK

... technologies allow small molecule hit and lead discovery at an unprecedented scale. This ... About Nuevolution Nuevolution is a leading lead discovery company founded in 2001 and based in ... which represents the ultimate fragment based lead discovery technology. Chemetics(R) enables rapid ...

Magellan Diagnostic Businesses to Feature Automated Systems and Diagnostic Tests at Clinical Lab Expo

... Robert J. Rosenthal, Ph.D. "Better diagnostics lead to more-informed treatment decisions and superior ... have missed those children most at-risk for lead poisoning, policy-makers at the federal, state, ... more-accurate diagnoses, breakthroughs that can lead to novel treatments, new cures -- innovations to ...

Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009

... in Q3 2009. - Santaris Pharma's new lead candidate SPC4955 targeting apoliproteinB, ... been selected for preclinical trials. - lead candidates targeting PCSK9, which is known to ... effectively. In Q2 2009 the Company selected a lead candidate SPC4955 for preclinical development. ...

ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference

... Kelly Larrabee, Director, Clinical Services, will lead a panel of life sciences executives on the topic ... Kelly Larrabee, Director, Clinical Services, will lead a panel of life sciences executives on the topic ... Larrabee was Manager and Regional Study lead for Pfizer, where she directed project site ...

Stem cells' 'suspended' state preserved by key step, scientists report

... pluripotent state. Exploiting the finding may lead to a greater understanding of how cells acquire ... the brain to develop the disease. It also could lead to treatments by directing the restored stem ... stem cell potential," said Alexandre Gaspar-Maia, lead author of the paper. "We found that Chd1 is ...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

... in which they demonstrate that DOR's lead product orBec(R) (oral beclomethasone ... of these pulmonary results is exciting as they lead the way to the potential development of new ... vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone ...

Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia

... now assembled an outstanding team to progress our lead candidate toward the clinic," stated Wendy ... cancer, inflammation and novel antibiotics. The lead candidate, CG100649 is a next generation NSAID ... structure-based novel scaffold/lead design, lead optimization and candidate selection with ADMET ...

Video: Varicose Veins, Much More Than a Cosmetic Issue, Can Prove a Health Risk

... as a cosmetic issue without recognizing they can lead to pain and discomfort. As many women often ... of faulty valves and weakened vein walls and can lead to pain swelling and fatigue in the legs. ... and worsen over time and, if untreated, could lead to serious complications, such as leg ulcers or ...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

... in benign prostatic hyperplasia (BPH) with its lead endocrinology compound, cetrorelix pamoate, is ... involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU ... extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of ...

AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

... involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU ... extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of ... involving 528 patients in North America. The lead investigator is Joel Kaufman, M.D., Associate ...

Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University

... macula, often leaking blood and fluid that can lead to visual distortions, a decrease or loss of ... vessels found in wet AMD patients. The lead compound from this technology platform has shown ... biotechnology companies to advance their lead drug candidates, Calvert Research has further ...

AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer

... with the Netherlands Cancer Institute. The lead investigator was Marcel Verheij, MD, Ph.D., Head ... daily). There were no safety signals that would lead to an amendment of the current safety data or ... expected range. Marcel Verheij, M.D., Ph.D., lead investigator, "The neutral outcome of this study ...

Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors

... observed in RP patients treated with NT-501 will lead to a benefit in visual function," stated Dr. ... of the Retina Foundation of the Southwest and lead investigator for the RP studies. "However, the ... for RP. About NT-501 Neurotech's lead product, NT-501, consists of encapsulated human ...

Proteon Therapeutics Completes Second Closing of Equity Financing; Raises Total Series B to $50 million

... also receives orphan drug designation for its lead product candidate, PRT-201 WALTHAM, Mass., ... previous investors. Proteon also disclosed its lead product candidate, PRT-201, received orphan drug ... failure rates. Improved maturation rates may lead to fewer corrective surgical procedures, ...

AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting

... or following treatment with LHRH agonists lead Author: Stephen Liu, MD Poster Session: 2 pm - ... therapy (Rx) with a VEGF receptor inhibitor. lead Author: Nicholas Vogelzang, MD Poster ... have failed tyrosine kinase inhibitors (TKI). lead Author: Daniel Cho, MD Poster Session: 2 pm - ...

Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology

... therapy (Rx) with a VEGF receptor inhibitor. lead Author: Nicholas Vogelzang, MD Poster ... failed tyrosine kinase inhibitors (TKI). lead Author: Daniel Cho, MD Poster Session: ... or third-line metastatic colon cancer. lead Author: Sasha Vukelja, MD Poster Session: ...

NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies

... (USD 54.8 million) to take back control of its lead compounds (NI-0401 and NI-0501, a fully human ... now has regained full control of two of its lead compounds from MerckSerono and is looking forward ... with the most advanced in clinical phase II. The lead product, NI-0401/anti-CD3, is currently ...

Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy

... and Empatic(TM)." In his role, Jay will lead corporate development at Orexigen, notably ... opportunities and commercialization strategy for lead products Contrave (naltrexone sustained release ... on the treatment of obesity. The Company's lead combination product candidates targeted for ...

ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs

... developed by The Proctor & Gamble Company. lead molecules from the portfolio have already been ... support to initiate human clinical trials with lead products ATI-0312 for HIV and ATI-0810 for HCV ... of the class of inhibitors. ImQuest will also lead Arisyn's efforts to develop next generation ...

Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program

... the highest quality NDA and bring Contrave, our lead obesity product candidate, to market expeditiously." In his role, Dr. Scaife will lead the development of Contrave (naltrexone sustained ... on the treatment of obesity. The Company's lead combination product candidates targeted for ...

Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board

... continued development," said Dr. Batts, who was lead investigator at the Upjohn Company for the ... caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation ... pipeline includes two preclinical programs with lead candidates being developed to treat serious ...

Putting the squeeze on an old material could lead to 'instant on' electronic memory

... devices are made with such materials as lead zirconium titanate or strontium bismuth ... materials in transistors, which could lead to "instant-on" computing no more rebooting the ... "Adding new functionality to transistors can lead to improved computing and devices that are lower ...

Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR

... angiopoietin/Tie2 pathway with AMG 386 lead author: Estrada J. Abstract No. 140 ... corneal macrophage recruitment in vivo lead author: Liu H. Abstract No. 1106 (Sunday, ... or Ang2 (L1-7(N)) alone or in combination lead author: Falcon B. Abstract No. 1996 ...

Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team

... make him a superb addition as we advance our lead anti-cancer product, carfilzomib, into late-stage ... for the advancement of carfilzomib, Proteolix's lead anti-cancer proteasome inhibitor for the ... for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class ...

Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals

... Therapeutics, Inc., the leader in fragment-based lead discovery for diseases of the central nervous ... biology, crystallography and fragment-based lead discovery expertise through partnerships, ... internal programs combine fragment-based lead discovery with the expertise of biologists and ...

Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments

... ) today released the following letter from its lead Independent Director, James N. Wilson, providing ... Dear Fellow Amylin Shareholder: As lead Independent Director of Amylin, I am writing you ... ("Eastbourne"). Also, in my capacity as lead Independent Director, I have talked to many ...

Arno Therapeutics Reports 2008 Year-End Financial Results

... development costs associated with AR-67, our lead clinical development compound which has completed ... in 2008 and achievements for Arno, as our lead drug candidate, AR-67 completed Phase I ... for the treatment of cancer patients. Arno's lead clinical development compound is AR-67, a novel, ...

Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge

... wounds, and if left untreated, this pain can lead to depression, loss of appetite, and immobility, ... About CollaRx CollaRx is Innocoll's lead technology platform for the site specific ... also forms the basis of Innocoll Pharmaceuticals' lead product, Gentamicin Surgical Implant, a ...

Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session

... Phase I clinical trial of AMR-001, the company's lead product for the treatment of damaged heart muscle ... following an AMI, ventricular remodeling can lead to permanent heart damage and increase the risk ... products to treat cardiovascular disease. Its lead product AMR-001, for the prevention of major ...

Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference

... data for a series of JAK2 inhibitors that lead to the identification of CYT387, the company's lead JAK2 drug candidate for the treatment of ... for the treatment of cancer. The company's lead drug candidate is CYT997, a vascular disrupting ...

Zinc oxide gives green shine to new photoconductors

... in baby powder and suntan lotion -- instead of lead sulfide. (Currently, the best performing photoconductor is based on lead sulfide nanoparticles.) The new material ... to get a good strong and clear signal," said lead researcher Samuel I. Stupp, Board of Trustees ...

Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning

... enables children and adults to be screened for lead poisoning faster, easier, and more conveniently. ... encouraging news about U.S. progress in reducing lead poisoning -- this crisis is by no means over. lead contamination remains a serious problem, and ...

TauTaTis Discovers Potent Inhibitor of Parkinson's Disease Gene Activity

... /PRNewswire/ -- TauTaTis, Inc. announces that its lead compound for inhibition of tau protein pathology, ... cause of Parkinson's Disease. TauTaTis' lead compound is a proprietary small molecule that has ... discovery significantly broadens the scope of our lead development program, which targets the biological ...

DOR BioPharma Appoints Brian L. Hamilton, MD, PhD as Chief Medical Officer

... at Wyeth and Astra, USA. Dr. Hamilton will lead DOR's clinical affairs, with an emphasis on the ... someone whose skill set provides a better fit to lead our clinical programs forward. His experience in ... vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone ...

AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results

... partnership with sanofi-aventis for our lead compound, cetrorelix. At the drug development ... 2009. We also made significant progress with our lead oncology compound, AEZS-108, in endometrial and ... the advancement of our Phase 3 program with our lead compound, cetrorelix, in BPH. Consolidated net ...

Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies

... analysis of high-throughput in vitro ADME assays, lead discovery and lead optimization services, and even a genetic ... These research endeavors ranged from lead compound discovery to single nucleotide ...

AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia

... involves 667 patients under the supervision of lead investigator, Herbert Lepor, MD, Professor at NYU ... extension conducted under the supervision of lead investigator, Prof. Frans M.J. Debruyne, MD, of ... involving 529 patients in North America. The lead investigator is Joel Kaufman, M.D., Associate ...

VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291

... Plaque", covering the use of VIA's lead compound, VIA-2291, for the treatment of ... existing intellectual property protection for our lead clinical compound." About VIA ... of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet ...

Amsterdam Molecular Therapeutics Reports Full Year Results 2008

... a delay of the announced filing date for lead product GlyberaTM which is now expected H2 2009 ... related to the development work on the company's lead product, GlyberaTM, increased staffing for this ... "Despite the setback in the filing date for AMT's lead product GlyberaTM, our Company made substantial ...